The Device Industry's Rx Marketing Dilemma
Executive SummaryThe big news out of this year's TCT meeting in September wasn't really news at all. The final results of the SIRIUS clinical trial, assessing restenosis rates and other clinical measures of the sirolimus-coated drug-eluting stent (now being marketed in Europe by Cordis Corp., a Johnson & Johnson operating company and soon to be available in the US) weren't all that different from the preliminary data previewed in May at the Paris Course on Revascularization.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.